Physician profile
Allyson Fahey
NPI 1083451520
$3,205.36
in general payments reported to CMS, 2019-2025
23 companies · $2,741 in 2025
The $2,741 reported for 2025 was more than what 95% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $464 · 2025: $2,741.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,205.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,195.32 | 2024-2025 | |
| Ucb, INC. | $284.86 | 2024-2025 | Rystiggo, Zilbrysq, Briviact |
| Pfizer INC. | $274.34 | 2025 | |
| Tg Therapeutics, INC. | $238.51 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $194.67 | 2025 | Hyqvia |
| Tanabe Pharma America, INC. | $107.99 | 2024-2025 | Radicava |
| Corium, LLC | $105.54 | 2024-2025 | Azstarys |
| Lilly USA, LLC | $94.12 | 2024-2025 | Kisunla |
| Axsome Therapeutics, INC. | $89.67 | 2025 | Symbravo |
| Lundbeck LLC | $88.42 | 2025 | Vyepti |
| Emd Serono, INC. | $77.47 | 2025 | |
| Tonix Medicines, INC. | $77.09 | 2025 | Zembrace Symtouch |
| Acadia Pharmaceuticals INC | $63.86 | 2025 | Nuplazid |
| Csl Behring | $62.92 | 2025 | Hizentra |
| Azurity Pharmaceuticals, INC. | $57.60 | 2025 | Horizant |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impel Pharmaceuticals LLC | $42.61 | 2025 | Trudhesa |
| Argenx US, INC. | $28.83 | 2025 | Vyvgart Hytrulo |
| Amgen INC. | $27.08 | 2025 | Uplizna |
| Novartis Pharmaceuticals Corporation | $24.62 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $21.31 | 2025 | Rexulti |
| Neurelis, INC. | $17.63 | 2025 | Valtoco |
| Merz Pharmaceuticals, LLC | $17.37 | 2025 | Xeomin |
| Neos Therapeutics, Lp | $13.53 | 2025 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allyson Fahey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.